Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

作者：W. Graydon Harker, Fredrick J. Meyers, Fuad S. Freiha, John M. Palmer, Linda Dairiki Shortliffe, John F. Hannigan, K M McWhirter, Frank M. Torti · 发表于：Journal of Clinical Oncology · 年份：1985 · DOI：10.1200/jco.1985.3.11.1463 · 被引用次数：352 · 研究领域：Bladder and Urothelial Cancer Treatments、Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders

Fifty-eight patients with metastatic transitional cell carcinoma of the urinary tract received cisplatin, methotrexate, and vinblastine (CMV) combination chemotherapy. Complete responses (CRs) were noted in 14 of the 50 (28%) evaluable patients and partial responses (PRs) in 14 patients for an overall response rate of 56% (95% confidence limits of 42% to 70%). The median duration of the 14 CRs was 9 months. Six of the 14 CRs (43%) remain in unmaintained remission from 6 + to 35 + months from onset of treatment. The median survival of evaluable patients receiving CMV was 8 months. Median survival for CRs was 11 months v 7 months for PRs (P less than .05) and 6 months for nonresponders. Renal and hematologic toxicities with this regimen were moderate. CMV is an effective regimen for patients with metastatic transitional cell carcinoma of the bladder. Prolonged disease-free survival may result from a CR to this regimen.